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EVALUATION OF BLOOD TRANSFUSION EFFECTS
ON MIXED VENOUS OXYGEN SATURATION AND
LACTATE LEVELS IN PATIENTS WITH SIRS/SEPSIS
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Hassmann
Mazza BF, Machado FR, Mazza DD, Hassmann V. Evaluation of blood transfusion effects on mixed venous oxygen saturation
and lactate levels in patients with SIRS/sepsis. Clinics. 2005;60(4):311-6.
PURPOSE: To evaluate the effects of red blood cell transfusion in patients with SIRS/sepsis who presented hemoglobin
levels under 9.0 g/dL at intensive care unit admission, using two parameters of organ perfusion: mixed venous oxygen
saturation and serum lactate levels.
METHODS: All patients admitted to the intensive care unit with SIRS/sepsis, as defined by Consensus Conference in 1992,
and hemoglobin levels under 9.0 g/dL were included. Hemoglobin levels, mixed venous oxygen saturation, and lactate
levels were collected before red blood cell transfusion (pre-T) and up to 1 hour after transfusion (post-T). These variables
were analyzed through a paired t test, and results were considered significant if P ≤ .05.
RESULTS: Twenty-nine patients (17 male, 12 female) with ages of 61.9 ± 15.1 (mean ± SD) years (range, 21-85 years) and
a mean APACHE II score of 12.5 ± 3.75 (7-21) were transfused with a mean of 1.41 packed red cell units. A significant
increase in hemoglobin levels was reached by blood transfusion, from 8.14 ± 0.64 g/dL (pre-T) to 9.4 ± 0.33 g/dL (post-T),
with P <.001. However, this was not accompanied by a significant change in lactate levels, from 1.87 ± 1.22 mmol/l (pre-T)
to 1.56 ± 0.28 mmol/l (post-T), with P =.28, or in mixed venous oxygen saturation, from 64.3 ± 8.52% (pre-T) to 67.4 ±
6.74% (post-T), with P = .13. The results were similar even in patients with hemoglobin levels under 8.0 g/dL (n = 9).
These results suggest that red blood cell transfusions, in spite of leading to a significant increase in hemoglobin levels, are
not associated with an improvement in tissue oxygenation in patients with SIRS/sepsis and hemoglobin levels < 9g/dL.
KEYWORDS: Red blood cell transfusion. Mixed venous oxygen saturation. Serum lactate. Tissue oxygenation. Sepsis.
Anemia is a common finding in patients admitted to the
ICU. Studies have shown that 77% of these patients present
anemia during their hospital stay, and more than one third
of them end up receiving a red blood cell transfusion.
Anemia is secondary to multiple factors. In addition to
blood loss provoked by evident bleedings, including ia-
trogenic anemia, which is caused by collection of blood
samples for exams, invasive procedures; nutrition failure;
hemolysis; occult blood loss; and endocrine, renal or he-
patic system alterations can also lead to a decrease in eryth-
ropoietin release, which causes a decreases erythropoiesis.1,2
On the other hand, it is known that the action of inflamma-
tory cytokines, such as tumoral necrosis factor (TNF-a),
interleukin-1 (IL-1), and interleukin-6 (IL-6), correlates to
a decrease of erythropoietin production. Interferon gamma
and IL-1 also seem to act directly, inhibiting the growth of
pro-erythrogenic cells, contributing to the development of
anemia in these patients.3
Thus, red blood cell transfusion has been often used on
patients admitted to ICU. Two studies assessed the incidence
of anemia and the use of blood transfusion in Europe and
the United States. The European study has shown a trans-
fusion rate of 37% during the ICU stay, whereas the Ameri-
can study shows that about 44% of ICU patients underwent
transfusion. The mean pretransfusion hemoglobin (Hb) val-
ues were 8.4 g/dL and 8.6 g/dL, respectively. However, both
studies show that transfusion was associated with a worse
prognosis.4,5 Moreover, blood transfusion has exhibited sev-
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eral adverse effects that must be assessed when deciding
whether to use it. Complications are described in about 20%
of transfusions6 and can be classified as infectious and non-
infectious. Among the infectious complications are the trans-
mission of agents, such as hepatitis B and C virus, HIV, cy-
tomegalovirus, and human T cell lymphotropic virus HTLV,
as well as the risk of Chagas and syphilis transmission,
among others. The noninfectious complications are related
to concomitant transfusions of leucocytes, such as fever,
alloimmunization, refractoriness to platelet transfusion,
acute lung injury, and immunossupression.7,8 A retrospec-
tive study has shown that blood transfusion was related to
a greater rate of hospital infection.10 Other undesirable ef-
fects caused by the use of blood-derived substances are lung
edema due to hypervolemia, hypothermia, coagulopathies,
and toxicity due to citrate.9
Thus, blood transfusion has poses a difficult problem
in ICUs, and there are still many controversial aspects re-
lated to its benefits, as well as to the risks of keeping lower
levels of Hb in patients. In a recent study, Hébert et al.11
did not find benefits related to keeping Hb between 10 and
12 g/dL, when compared to a group with Hb between 7 and
9 g/dL, in ICU patients. However, when the subgroup of
patients with previous heart disease was analyzed, the re-
strictive strategy was associated with an increased death risk
in these patients.
Patients with SIRS/sepsis usually present abnormalities
in oxygen consumption. The treatment of these patients
aims at optimizing tissue oxygen extraction through the
maintenance of an adequate oxygen delivery, reducing the
progression of cell dysfunction, and hence, avoiding a mul-
tiple organ dysfunction syndrome.12 Mixed venous oxygen
saturation (SvO2) and serum lactate are valuable markers in
the assessment of cell metabolism as indirect measures of
oxygen tissue delivery, and are therefore important vari-
ables in monitoring patients admitted to ICU. Monitoring
of SvO2 evaluates the balance between the delivery and
consumption of oxygen, which is decreased when there is
a delivery decrease and/or a consumption increase. The pres-
ence and persistence of high levels of lactate are related to
increases in morbidity and mortality.13,14
The maintenance of adequate Hb levels was suggested
as a way of increasing the tissue oxygen delivery when
SIRS/sepsis occurs, leading to an improvement in tissue
hypoperfusion.15 In a recent study, the early optimization
of SvO2 has shown itself efficient concerning mortality re-
duction in patients with severe sepsis. Part of that strategy
was based on keeping the hematocrit above 30%.20 But
transfusion can also provoke a decrease in tissue oxygen
delivery because of the reduction in tissue flow in the mi-
crocirculation, deriving from increased blood viscosity.
This effect would become more severe when stored blood
is used, since the red cell morphology is compromised and
the function of 2,3-diphosphoglycerate (2,3 DPG) altered,
provoking a decrease in oxygen delivery.17,18
There are no definite data concerning the ideal value
of Hb for patients admitted to the ICU.16 This study aims at
determining the effect of blood transfusion on tissue oxy-
gen delivery as assessed by SvO2 and serum lactate in pa-
tients with SIRS/sepsis with Hb levels < 9 g/dL.
METHODS
The study was performed in a general ICU from Febru-
ary 2001 to October 2002. The protocol was approved by
the Ethics Committee of the institution, and all the patients
or their legal representatives agreed with their participation.
Patients with minimum age of 15 years were included when
they met the following inclusion criteria:
• Diagnosis of SIRS/sepsis, determined by the presence
of, at least, 2 of the criteria of the Consensus Conference
of 199219:
- Core temperature > 38°C or < 36°C;
- Heart rate > 90 beats per minute;
- Respiratory rate > 20 inhalations per minute or
PaCO2 < 32 mm Hg;
- WBC count higher than 12,000/mm3 or lower than
4,000/mm3 or with more than 10% immature forms
(bands);
• Hb< 9.0 g/dL;
• Invasive hemodynamic monitoring with Swan-Ganz
catheter with occluded pulmonary artery pressure > 12
mm Hg, as a marker of normovolemic status.
The exclusion criteria were pregnancy, brain death, or
expected death in less than 24 hours.
Blood was collected from all patients in order to analyze
Hb concentration, SvO2 through the distal lumen of the
Swan-Ganz catheter, and arterial lactate immediately before
the start of transfusion (pre-T) and 1 hour after the end of
the red blood cell transfusion (post-T). The number of red
blood cells to be transfused was determined by the initial
Hb rate: 1 packed red blood cell unit in patients with Hb
level between 8 and 9.0 g/dL, 2 packed red blood cell units
when they presented Hb level between 7 and 8 g/dL, and 3
packed red blood cell units when the Hb level was lower
than 7 g/dL.
Analyzing the results, we considered both the total
group of patients as well as the subgroup with Hb between
8 and 9 g/dL (Group 8-9) and the subgroup with Hb lower
than 8 g/dL (Group < 8). The data were expressed as mean
± standard deviation and analyzed by the ANOVA test. The
results were considered significant when P < .05. As our
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sample is small, a power analysis was performed. A differ-
ence of 5% in SvO2 and 0.5 mmol/k in lactate levels was
considered clinically significant. Based on these values as
the expected difference and on our own data, the power of
each analysis (global, Group 8-9, and Group <8) was deter-
mined.
RESULTS
Twenty-nine patients with ages of 62 ± 15 years were
included (17 men and 12 women). The mean APACHE II
was 12.5 ± 3.75. (Table 1). There were 20 patients in Group
8-9 and 9 in Group < 8. No immediate complications were
noticed after the blood transfusion.
Blood transfusion led to a significant increase of Hb lev-
els. The pre-T value was 8.14 ± 0.64 g/dL, increasing to
9.4 ± 0.33 g/dL (P < .001) post-T. The patients in Group 8-
9 presented Hb levels of 8.5 ± 0.27 g/dL (pre-T) and 9.47 ±
0.36 (post-T). Patients in Group < 8 presented 7.34 ± 0.48
g/dL (pre-T) and 9.23 ± 0.20 (post T) (both with P < .001)
(Tables 2, 3, and 4).
The SvO2 and the serum lactate showed only mild al-
teration in post-T values when compared to pre-T (this ap-
plies to the total group and the subgroup analysis), with-
out any significant statistical difference. The results of the
SvO2 varied from 64.3 ± 8.52 (pre-T) to 67.4 ± 6.74 (post-
T), with P =.13. Similar results were observed when the sub-
groups were considered. The SvO2 results in Group 8-9 were
65.8 ± 8.88 (pre-T) and 69.7 ± 6.15 (post-T), with P = .11;
and in Group < 8 SvO2 results were 62.4 ± 5.22 (pre-T) and
62.4 ± 5.32 (post-T), with P > .99 (Table 2, 3, and 4).
As for the serum lactate, results were similar, without any
significant alterations in the patients who received blood
transfusion. The lactate values for all patients were 1.87 ±
1.22 mmol/k (pre-T) and 1.56 ± 0.93 mmol/k (post-T), with
P = .28. The subgroups did not present significant altera-
tions either. In Group 8-9 the serum lactate values were 1.79
± 1.25 mmol/k (pre-T) and 1.39 ± 0.96 mmol/k (post-T),
with P = .26. In Group <8, the lactate values were 2.04 ±
1.2 mmol/k (pre-T), and 1.92 ± 0.8 mmol/k (post-T), with P
= .806 (Table 2, 3, and 4).
DISCUSSION
In this study we tried to assess the response to transfu-
sion through SvO2 and serum lactate. Despite the efficacy
Table 1 - General features of the patients
Patient Age Sex Diagnosis Apache Initial Initial Initial Lactate
il score HB(g/dL) SVO2 (%) (mmol/L)
1 56 male Pneumonia 13 8.5 62 1.20
2 66 male Mesenteric infarction (PO) 19 8.3 54 6.30
3 71 male Urinary infection 16 8.8 77 0.88
4 62 male Pneumonia 11 7.6 52 0.59
5 73 male Pancreatitis 15 8.0 56 2.81
6 42 female Polytrauma 8 8.5 60 2.85
7 71 male Colectomy (PO) 11 8.9 62 2.50
8 4 2 male Polytrauma 8 8.4 69 1.14
9 71 female Pneumonia 13 7.4 73 1.13
10 45 female Pancreatitis 18 8.6 76 2.00
11 81 male Urinary infection 15 7.4 61 2.54
12 64 female Aortic aneurysm (PO) 10 7.9 58 2.24
13 71 male Aortic iliac graft (PO) 10 8.3 78 0.85
14 56 female Total hip replacement (PO) 8 8.8 74 1.43
15 61 female Pneumonia 11 8.7 70 0.80
16 70 female Gastrectomy (PO) 11 8.6 51 1.57
17 52 male Polytrauma 14 8.9 60 0.90
18 53 male Pancreatitis 17 8.5 64 1.57
19 78 male Colectomy (PO) 12 6.9 62 4.48
20 80 male Pneumonia 14 7.7 63 1.64
21 21 female Appendicitis (PO) 8 7.4 58 2.73
22 53 male Total hip replacement (PO) 7 8.2 50 1.63
23 72 male Aortic iliac graft (PO) 10 8.2 76 1.65
24 39 female Polytrauma 8 6.3 67 2.31
25 72 female Colectomy (PO) 10 8.3 53 2.46
26 55 male Pancreatitis 13 7.5 64 0.74
27 52 male Intestinal obstruction (PO) 14 8.1 71 1.21
28 85 female Pneumonia 18 8.5 74 1.05
29 82 female Urinary tract infection 21 8.8 72 0.97
PO – postoperative, HB – hemoglobin, SVO2 - mixed venous oxygen saturation
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of transfusions i.e., the significant increase of Hb levels,
there was no improvement regarding the indirect markers
of tissue perfusion. It may be argued that such small differ-
ences in hemoglobin levels would not be enough to change
tissue perfusion. However, in clinical practice, the value of
9.0 g/dL is considered a cutoff level, below which the
perfusion would be compromised. Actually, this level is cur-
rently used as a transfusion threshold in many intensive
care units. Based on this, it was considered as a target in
the present study.
The SvO2 and the serum lactate are considered the best
markers of tissue oxygen delivery, and they can be used as
a guide in clinical practice. The normal value for the SvO2,
and the therapeutic goal in septic shock, is > 70%. Rivers
et al. used central venous oxygen saturation (SvcO2) > 70%
as a target in the initial period of resuscitation in patients
with septic shock, and they were able to demonstrate a sig-
nificant decrease in hospital mortality.20
In our protocol we used mixed venous oxygen satura-
tion, a more reliable marker than SvcO2 in terms of global
tissue perfusion, and the observed values were very low. The
correct clinical procedure is to increase oxygen delivery.
The question is whether this should be done through a red
blood cell transfusion or through volume replacement, ei-
ther with colloids or crystalloids, or even with dobutamine.
Rivers et al.20 showed that patients who did not have
their SvcO2 normalized after volume replacement and use
of vasoconstrictors received blood transfusion until the
hematocrit reached 30%. Only after that was dobutamine
given. Through this approach, they claim a significant de-
crease in mortality. However, they do not mention either
the percentage of patients that effectively presented an im-
provement in SvcO2 after transfusion or the extent of that
improvement, and did not consider the alterations in serum
lactate levels. Our study shows that transfusion was not ef-
ficient in optimizing SvO2, nor in causing lactate to return
to normal levels, although the majority of patients did reach
a hematocrit of 30%, That seems to suggest that transfu-
sions could work through volemic improvement rather than
through oxygen-carriage optimization. It is possible that
volemic improvement was responsible for the SvO2 increase
with a consequent decrease in mortality. It is known that
the use of crystalloids or colloids increases the tissue oxy-
gen delivery due to an increase in preload and better car-
diac output. Unfortunately, we did not record post-T pul-
monary capillary pressure values, which would show
whether the volemic status was improved by transfusion in
our patients. Nonetheless, increasing effectively the Hb lev-
els did not improve the oxygen tissue delivery in our study.
On the other hand, Hébert et al.11 reported that a restric-
tive strategy in terms of blood transfusions was adequate,
with a mortality rate lower than that observed in the group
that received more transfusions. However, this difference was
not statistically significant. Therefore, that study suggests
that Hb levels over 7.0 g/dL are sufficient to guarantee ad-
equate oxygen delivery. It is notable that those authors as-
sessed a general population of critically ill patients and not
specifically a septic population of patients. Due to the pe-
culiarities of septic patients, such as, cytopathic hypoxemia
21 and microcirculatory thrombosis, which impairs blood
flow,22 it is possible that these patients have a different re-
sponse to low levels of Hb. Had a septic population been
studied, results might have been worse in terms of mortal-
ity reduction.
Moreover, because of the deficient circulation, the prob-
lems derived from the stored-blood transfusion are also po-
tentially higher, as these red cells exhibit decreased rheologic
Table 4 - Hemoglobin, mixed venous oxygen saturation and
serum lactate pre and post-transfusion in the subgroup with
hemoglobin < 8g/dL
Pre- Post- P#
Transfusion Transfusion
Hemoglobin (g/dL) 7.34± 0.48* 9.23± 0.20* <0.0001
SvO2 (%) 62.4± 5.22** 62.4± 5.32** 1
Serum lactate (mmol/l) 2.02± 1.20*** 1.92± 0.80*** 0.80
# ANOVA. Power analysis: SvO2 = 0,94, serum lactate = 0.47; All
results are expressed in mean±standard deviation; SvO2 - Mixed
venous oxygen saturation
Table 3 - Hemoglobin, mixed venous oxygen saturation and
serum lactate pre- and post-transfusion in the subgroup with
hemoglobin between 8-9 g/dL
Pre- Post- P#
Transfusion Transfusion
Hemoglobin (g/dL) 8.5 ± 0.027* 9.4 ± 0.36* <.001
SvO2 (%) 65.8 ± 8.88** 69.7 ± 6.10** .11
Serum lactate (mmol/l) 1.79 ± 1.25*** 1.39 ± 0.26*** .26
# ANOVA. Power analysis: SvO2 = .93, serum lactate > .99; All results
are expressed in mean ± standard deviation; SvO2 - Mixed venous
oxygen saturation
Table 2 - Hemoglobin, mixed venous oxygen saturation and
serum lactate pre- and post-transfusion global analysis
Pre- Post- P#
Transfusion Transfusion
Hemoglobin (g/dL) 8.14 ± 0.64 9.4 ± 0.33 <.001
SvO2 (%) 64.3 ± 8.52 67.4 ± 6.74 .13
Serum lactate (mmol/l) 1.87 ± 1.22 1.56 ± 0.93 .28
# ANOVA. Power analysis: SvO2 = .99, serum lactate >.99; All results
are expressed in mean ± standard deviation; SvO2 - Mixed venous
oxygen saturation
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properties and an alteration in 2,3 DPG.23 This could lead to a
decrease in the oxygen-delivery capacity of these cells. Thus,
the transfusion would not only fail to have any effect in the
optimization of the tissue oxygen delivery, but might also con-
tribute to the altered values of the venous oxygen saturation
and serum lactate. The mean time of blood storage in the hos-
pital where the study was performed is 15 days.
One possible explanation for the absence of alterations in
tissue oxygenation parameters would be that the hemoglobin
levels were not low enough to contribute to a decrease in tis-
sue oxygen delivery, because the mean value of Hb was 8.14
± 0.64 g/dL. It is possible that the basic problem of the pa-
tients was not the hemoglobin, but rather the volemic status
or even the myocardial depression related to sepsis. Even so,
we can still suppose those Hb levels are sufficient to guaran-
tee an adequate oxygen transport in this population.
One limitation of our study is the small number of pa-
tients. It is possible that due to the small power, a type 2
error may have occurred. Nonetheless, statistical analysis
showed high power to detect clinically significant differ-
ences in SvO2 and serum lactate, with exception of the former
in the subgroup of patients with HB < 8.0g/dL. In this small
subgroup, as the number of individuals is too low, the re-
sults could be questionable, and a type 2 error is possible.
However, this is the group whose response to transfusion
was supposed to be more pronounced, and values for SvO2
and lactate were nearly unchanged. This suggests that a sig-
nificant difference does not exist, and even with a larger
sample we would not be able to demonstrate it.
Another limitation is the age variability in our group of
patients. It is known that transfusion effects can be very dif-
ferent in young patients comparing to older ones. In the
CRIT study,5 the detrimental effects of transfusion were sig-
nificant only in the subgroup of patients under 55 years. This
might be related to a high incidence of ischemic cardiovas-
cular disease in the older group. Therefore, it is possible that
the benefits of transfusion in our group were obscured due
to this great variability. However, although the mean age was
similar in both studies (62 ± 15 years and 60 ± 18 years, re-
spectively) only 17% of our patients were younger than 50
years compared to 30% in the CRIT study. This finding sug-
gests that if there is a benefit in transfusion, it would have
been easier to prove it in our population than it would in an
older one. Unfortunately, a subgroup analysis was precluded
by the small number of patients in both groups.
In conclusion, the significant increase of Hb levels af-
ter blood transfusion that occurred in our studied groups,
was not accompanied by alterations of SvO2 and lactate lev-
els. This result suggests that a more restrictive strategy re-
lated to blood transfusion should be used on patients ad-
mitted to the ICU.
The risks and benefits of blood transfusions must always
be taken into account, even when the patients present a tis-
sue oxygen delivery failure.
RESUMO
Mazza BF, Machado FR, Mazza DD, Hassmann V. Avaliação
dos efeitos da transfusão de sanguínea na saturação venosa
mista e nos níveis de lactato em pacientes com SIRS/sepse.
Clinics. 2005;60(4):311-6.
OBJETIVOS: Avaliar o efeito da transfusão de hemáceas
em pacientes com SIRS/sepse que apresentaram níveis de
hemoglobina abaixo de 9,0g/dL durante internação em
unidade de terapia intensiva, usando dois parâmetros de
perfusão orgânica, a saturação venosa mista de oxigênio e
os níveis de lactato sérico.
MÉTODOS: Todos os pacientes admitidos na Unidade de
Terapia Intensiva com SIRS/sepse, como definido pela
Conferência de Consenso de 1992, e níveis de hemoglobina
abaixo de 9,0g/dL foram incluídos. Os níveis de
hemoglobina, saturação venosa mista de oxigênio e lactato
sérico foram coletados antes (pré-T) e após uma hora da
transfusão de hemáceas (pós-T). Essas variáveis foram
analisadas através do teste T de Student pareado e os
resultados considerados significativos se p<0,05.
RESULTADOS: Vinte e nove pacientes (17 homens e 12
mulheres) com idade média de 61,9±15,1 anos (21-85anos) e
índice APACHE II de 12.5±3.75 (7-21) foram transfundidos
com uma média de 1,41 unidades de hemáceas. Um aumento
significativo dos níveis de hemoglobina foi atingido com a
transfusão: 8,14g/dL±0,64 (pré-T) e 9,4±0,33g/dL (pós-T), com
p<0,0001. Entretanto, isso não foi acompanhado por mudança
significativa dos níveis de lactato: 1,87±1,22mmol/l (pre-T) e
1,56±0,28mmol/k (pós-T), com p=0,28, ou da saturação venosa
mista de oxigênio: 64,3±8,52% (pre-T) e 67,4±6,74% (pós-
T), com p=0,13. Os resultados foram semelhantes mesmo nos
pacientes com hemoglobina abaixo de 8,0g/dL. Todos os
resultados estão expressos em média ± desvio padrão
Esses resultados sugerem que transfusões de hemácias,
apesar de levarem a aumento significativo dos níveis de
hemoglobina, não estão associadas à melhora da
oxigenação tecidual em pacientes com SIRS/sepse e
hemoglobina abaixo de 9,0g/dL.
UNITERMOS: Transfusão de hemácias. Saturação venosa
mista de oxigênio lactato sérico. Oxigenação tecidual.
Sepse.
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